Premium
Interferon therapy for renal cell carcinoma in hemodialysis patients: Report of two patients
Author(s) -
Hanazawa Kisaburo,
Tanaka Michio,
Watanabe Ryota,
Fujime Makoto
Publication year - 2000
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1046/j.1442-2042.2000.00158.x
Subject(s) - medicine , hemodialysis , renal cell carcinoma , interferon , alpha interferon , urology , alpha (finance) , carcinoma , gastroenterology , renal function , endocrinology , immunology , surgery , construct validity , patient satisfaction
The method of interferon therapy has not been clarified in hemodialysis patients with renal cell carcinoma. Two hemodialysis patients with renal cell carcinoma were treated with natural interferon‐α. The serum levels of interferon‐α in both patients were measured after 24, 48, 72 and 96 h of injection. In case 1, the serum concentration of interferon‐α after 24 h of injection at a dose of 3 × 10 6 reached a maximum and decreased gradually. In case 2, the serum concentration of interferon‐α reached a maximum 24 h after injection at a dose of 3 × 10 6 and decreasing gradually after this. After an injection of interferon‐α at a concentration of 6 × 10 6 7 days later, the serum concentration of interferon‐α reached a maximum 48 h after the injection and decreased gradually thereafter. The serum interferon‐α concentrations of these cases were higher than normal renal function patients in other literature. It is necessary to modify the interval between injections for hemodialysis patients with renal cell carcinoma.